TITLE

GENTIUM COMPLETES PRECLINICAL/CLINICAL DEFIBROTIDE STUDIES

PUB. DATE
March 2011
SOURCE
Worldwide Biotech;Mar2011, Vol. 23 Issue 3, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article provides information on a drug developed by Gentium S.p.A. in Italy, called defibrotide, for the prevention and treatment of veno-occlusive disease (VOD), a life threatening condition of the liver that occur when a patient undergoes stem cell transplant. A detailed description of VOD is provided. In the research study led by Gentium Scientific director Massimo Iacobelli, the drug is reported to have no side effects on rats and healthy human volunteers, while pregnant rats showed maternal toxicity and intrauterine development of the progeny.
ACCESSION #
58691936

 

Related Articles

  • Gentium Voluntarily Pulls NDA For Defibrotide; Shares Tumble. Powers, Marie // BioWorld Today;8/19/2011, Vol. 22 Issue 161, p1 

    This article reports on the voluntary withdrawal by Gentium SpA of its new drug application (NDA) for defibrotide. The company took the move 36 hours after receiving a letter from the Food and Drug Administration ( FDA) which cited a number of issues regarding the NDA for defibrotide. The drug...

  • Gentium Announces NDA Submission for Defibrotide.  // Worldwide Biotech;Aug2011, Vol. 23 Issue 8, p2 

    The article reports on a new drug application (NDA) submitted by Gentium SpA to the U.S. Food and Drug Administration (FDA) for Defibrotide for the treatment of hepatic veno-occlusive disease (VOD) in patients undergoing hematopoietic stem-cell transplantation (HSCT). The drug has allegedly been...

  • Concerns Raised on Gentium's Phase III Study.  // Bioworld Week;6/16/2008, Vol. 16 Issue 24, p2 

    The article reports on the suggestion of an independent data safety monitoring board (DSMB) for Gentium SpA to confirm the criteria for a Phase III trial of its defibrotide in the U.S. Gentium is asked to confirm the criteria used to select historical control patients for the trial of its...

  • Gentium Shares Take Beating on Concerns About Study. Turner, Tiffany // BioWorld Today;6/9/2008, Vol. 19 Issue 111, p1 

    The article reports on the decrease in stock of Gentium SpA in June 2009 on news that an independent data safety monitoring board (DSMB) recommended that the company confirm the criteria used to select historical control patients for a Phase III trial of its lead product, defibrotide, in...

  • Gentium Shares Falling as Defibrotide Faces Delay Again. Sheridan, Cormac // BioWorld Today;2/25/2013, Vol. 24 Issue 36, p1 

    The article reports that share prices for Gentium SpA has fallen 20 percent due to the delayed approval of the drug defibrotide. The drug is developed for the treatment and prevention of hepatic veno-occlusive disease (VOD) in patients undergoing hematopoietic stem cell transplant. Preliminary...

  • Gentium Voluntarily Pulls NDA For Defibrotide; Shares Tumble.  // Bioworld Week;8/22/2011, Vol. 19 Issue 33, p5 

    The article reports on the decline in August 2011 shares of Gentium SpA in the aftermath of its announcement on its voluntary withdrawal of the new drug application (NDA) for defibrotide in 2011 in the U.S.

  • Gentium's Defibrotide Brings 2Q Sales Record as Launch Looms. Sheridan, Cormac // BioWorld Today;8/14/2013, Vol. 24 Issue 155, p1 

    The article reports on the high sales record posted by Gentium SpA for its Defitelio (defibrotide) drug product in the second quarter of 2013. It describes the mechanism of action of the drug used for the prevention or treatment of hepatic veno-occlusive disease (VOD) in patients undergoing...

  • Gentium Shares Falling as Defibrotide Faces Delay Again. Sheridan, Cormac // BioWorld International;2/27/2013, Vol. 18 Issue 9, p1 

    The article reports on the 20% decline of shares in Gentium SpA as the approval process for defibrotide, which is a drug treatment for hepatic veno-occlusive disease (VOD) in patients undergoing hematopoietic stem cell transplant, faces delay. Salvatore Calabrese, chief financial officer at...

  • The aging liver. Drug clearance and an oxygen diffusion barrier hypothesis. Le Couteur, D.G.; McLean, A.J. // Clinical Pharmacokinetics;1998, Vol. 34 Issue 5, p359 

    A change in drug clearance with age is considered an important factor in determining the high prevalence of adverse drug reactions associated with prescribing medications for the elderly. Despite this, no general principles have been available to guide drug administration in the elderly,...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics